1M6MYTD1Y5YMAX
Loading quotes...
Forecast
The analysts' average price target is €7.31 (+27.57%). The median is €7.31 (+27.57%).
| Buy |
3 |
| Hold |
0 |
| Sell |
0 |
News Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
| (EUR) | June 2026 | |
|---|---|---|
| Revenue | 0 | - |
| Gross profit | 0 | - |
| Net profit | -45.55M | 2,641.40% |
| EBITDA | -45.55M | 2,641.60% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €4.91M |
Number of shares | 959.64K |
52-week high/low | €9.24 - €1.13 |
| Dividends | No |
Beta | 1.43 |
P/E ratio | -0.36 |
PEG ratio | 0.01 |
P/B ratio | 176.28 |
P/S ratio | 0.00 |
Company profile
| Name | Adial Pharmaceuticals Inc |
| CEO | Cary John Claiborne |
| Employees | 5 |
Discover assets
Shareholders of Adial Pharmaceuticals Inc also invest in the following assets
